“…The procedures of collecting and handling the serum samples were approved by USM Human Ethical Committee (reference number USMKK/PPP/ JEPem[213.3(10)]). Human serum samples included in this study were divided into four groups: (i) group A, human ALA serum samples (n ϭ 24) with consistent clinical symptoms (i.e., fever, abdominal/right hepatic chest pain, hepatomegaly, and jaundice) and radiological image and IHA-positive results; (ii) group B, human ALA serum samples (n ϭ 14) from patients whose abscesses were positive by real-time PCR for E. histolytica DNA and negative by bacterial culture (the primers and probe sequences were as reported previously [9]); (iii) group C, healthy blood donor serum samples which were negative by IHA (n ϭ 30); (iv) group D, serum samples from patients with other infections (n ϭ 33), i.e., salmonellosis (n ϭ 5), shigellosis (n ϭ 1), Escherichia coli septicemia (n ϭ 2), Staphylococcus sp. septicemia (n ϭ 2), Helicobacter pylori (n ϭ 6), pyogenic liver abscess (n ϭ 4), Stenotrophomonas maltophilia septicemia (n ϭ 1), enteropathogenic E. coli (n ϭ 1), Ascaris lumbricoides (n ϭ 1), Klebsiella pneumoniae (n ϭ 1), and toxoplasmosis (n ϭ 9).…”